The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. 2018 was a difficult year; however, the index still outperformed its comparative London indices, falling 10.0% to 393.2, compared with -13.0% and - 18.2% for the Allshare index and the AIM index, respectively. Furthermore, several (17) companies in our index increased their capital base – 15 of our 50 constituents rai
11 Jan 2019
THE MONTHLY January 2019
Time Finance plc (TIME:LON), 42.5 | Allergy Therapeutics plc (AGY:LON), 3.2 | Alliance Pharma plc (APH:LON), 34.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,025 | Avacta Group PLC (AVCT:LON), 45.5 | Burford Capital Limited (BUR:LON), 1,254 | City of London Investment Group PLC (CLIG:LON), 348 | DP Poland PLC (DPP:LON), 11.2 | Gateley (Holdings) Plc (GTLY:LON), 116 | Genedrive Plc (GDR:LON), 2.0 | Haydale Graphene Industries Plc (HAYD:LON), 0.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 316 | Palace Capital plc (PCA:LON), 239 | Primary Health Properties PLC (PHP:LON), 96.2 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 61.5 | Titon Holdings Plc (TON:LON), 85.0 | Volta Finance Limited (VTA:LON), 504 | ValiRx PLC (VAL:LON), 3.0 | Redx Pharma Plc (0RX:FRA), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
THE MONTHLY January 2019
Time Finance plc (TIME:LON), 42.5 | Allergy Therapeutics plc (AGY:LON), 3.2 | Alliance Pharma plc (APH:LON), 34.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,025 | Avacta Group PLC (AVCT:LON), 45.5 | Burford Capital Limited (BUR:LON), 1,254 | City of London Investment Group PLC (CLIG:LON), 348 | DP Poland PLC (DPP:LON), 11.2 | Gateley (Holdings) Plc (GTLY:LON), 116 | Genedrive Plc (GDR:LON), 2.0 | Haydale Graphene Industries Plc (HAYD:LON), 0.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 316 | Palace Capital plc (PCA:LON), 239 | Primary Health Properties PLC (PHP:LON), 96.2 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 61.5 | Titon Holdings Plc (TON:LON), 85.0 | Volta Finance Limited (VTA:LON), 504 | ValiRx PLC (VAL:LON), 3.0 | Redx Pharma Plc (0RX:FRA), 0
- Published:
11 Jan 2019 -
Author:
Hardman & Co Research Team -
Pages:
40
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. 2018 was a difficult year; however, the index still outperformed its comparative London indices, falling 10.0% to 393.2, compared with -13.0% and - 18.2% for the Allshare index and the AIM index, respectively. Furthermore, several (17) companies in our index increased their capital base – 15 of our 50 constituents rai